This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Lies Ahead for Pfizer ETFs After Another Round of Upbeat Vaccine Data
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in the coronavirus vaccine development.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Q3 Earnings Fail to Impress Pharma ETFs
by Sweta Killa
The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.
Nasdaq Pharmaceuticals ETF (FTXH) Hits a 52-Week High
by Sweta Jaiswal, FRM
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
Pharma ETFs Gain on Healthy Q4 Earnings
by Sweta Killa
Strong results led to solid trading in pharma ETFs over the past week.
Pharma ETFs Set to Benefit Post Strong Q3 Earnings
by Sweta Killa
Robust results led to solid trading in pharma ETFs in a month.
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?
by Sweta Killa
Despite robust results, pharma ETFs have been trending downward in a month.
Pharma ETFs Down Despite Solid Q1 Results
by Sweta Killa
Despite such robust results, pharma ETFs have been trending downward in a month.